title: Clinicopathological features and medical management of intraductal papillary mucinous neoplasms.
abstract: BACKGROUND
  Intraductal papillary mucinous neoplasms (IPMN) are a clinicopathological entity that is being diagnosed with increasing frequency. However, the best approach to medical management of IPMN needs to be clarified. The aim of the present study was to identify preoperative features that may be predictors of malignant IPMN, and to define the medical management of IPMN of the pancreas.
  
  
  METHODS
  A total of 23 patients who underwent surgical resection for IPMN of the pancreas at Kochi Medical School between 1982 and 2004 were examined. Multivariate Cox regression analysis was used to identify factors independently associated with IPM carcinoma.
  
  
  RESULTS
  Among the 23 patients, 12 had IPMN adenoma, three had borderline IPMN, four had IPMN with carcinoma in situ, and four had IPMN with invasive carcinoma. In multivariate analysis, elevated serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 levels were found to be preoperative predictors of malignant IPMN. These results suggest that the following IPMN of the pancreas should be resected: (i) IPMN of the pancreas situated in the main duct; (ii) IPMN located in the branch duct if the size of the cystic lesion is >30 mm and the mural nodules are >5 mm in height by endoscopic ultrasound (EUS); and (iii) the diameter of the main pancreatic duct is >10 mm by endoscopic retrograde pancreatography (ERP). Careful observation of patients with branch-type IPMN with small cysts and/or without mural nodules is recommended as a management strategy.
  
  
  CONCLUSIONS
  The present study reinforces the need for immediate surgical resection of malignant IPMN and suggests indicators for IPMN that should assist physicians in making decisions on treatment options.
authors.affiliation: Department of Tumor Surgery, Kochi Medical School, Kochi, Japan. tokabaya@med.kochi-u.ac.jp
authors.forename: Takehiro
authors.initials: T
authors.lastname: Okabayashi
authors.forename: Michiya
authors.initials: M
authors.lastname: Kobayashi
authors.forename: Isao
authors.initials: I
authors.lastname: Nishimori
authors.forename: Takeki
authors.initials: T
authors.lastname: Sugimoto
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Namikawa
authors.forename: Ken
authors.initials: K
authors.lastname: Okamoto
authors.forename: Nobuto
authors.initials: N
authors.lastname: Okamoto
authors.forename: Takuhiro
authors.initials: T
authors.lastname: Kosaki
authors.forename: Saburo
authors.initials: S
authors.lastname: Onishi
authors.forename: Keijiro
authors.initials: K
authors.lastname: Araki
mesh_terms: D002288:Adenocarcinoma, Mucinous / Q000175:diagnosis* / Q000601:surgery*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002760:Cholangiopancreatography, Endoscopic Retrograde; D003937:Diagnosis, Differential; D019160:Endosonography; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010180:Pancreatectomy; D010190:Pancreatic Neoplasms / Q000175:diagnosis* / Q000601:surgery*; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome